Nike Earnings Reveal Weak Sales and Pace Restructuring

Nike earnings showed weaker sales and unveiled Pace, a restructuring that targets $2.5B in savings and will reduce roles, pressuring the fiscal outlook.

October 01, 2026·2 min read
View all news articles
Flat-vector running shoe fused with a factory, symbolizing Nike earnings and Pace restructuring's savings focus.

KEY TAKEAWAYS

  • Revenue was $11.2B, down 4.0% year over year.
  • Introduced Pace, targeting $2.5B in cumulative savings through fiscal 2031.
  • Pace carries about $1.0B of pretax charges, including roughly $300M in fiscal 2027.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Nike earnings were mixed on Oct. 1, 2026, as the company reported softer sales and introduced "Pace," an operating-model restructuring it said will deliver multiyear savings and reduce roles across the company.

Quarterly Results and Outlook

Nike reported revenue of $11.2 billion for the quarter ended Aug. 31, 2026, down 4.0% year over year on a reported basis and 5.0% on a currency-neutral basis. Net income declined 2.0% to $712 million from $727 million a year earlier. Diluted earnings per share (EPS) were $0.48, compared with $0.49 in the prior-year quarter and above the roughly $0.43 consensus.

Gross margin expanded 60 basis points to 42.8%, while selling and administrative expenses fell about 3.0% to roughly $3.9 billion. Management described uneven regional performance: Greater China revenue dropped 26.0%, EMEIA declined 5.0%, APGC was flat, and North America rose 2.0%. These patterns, along with deliberate shifts involving Nike Sportswear and Jordan Brand, contributed to near-term sales pressure.

For fiscal 2027, which runs through May 31, 2027, Nike expects revenue to decline in the high-single-digit percentage range. The company projects adjusted diluted EPS of $1.15 to $1.35, excluding approximately $0.15 per share of Pace-related restructuring expense.

Pace Restructuring and Workforce Impact

Nike introduced Pace as an operating-model transformation designed to accelerate and scale the Sport Offense strategy. The program includes supply-chain modernization, a reorganization into three geographic regions, construction of a new campus in India, and changes to workforce responsibilities.

Nike expects Pace to generate about $2.5 billion in cumulative savings through fiscal 2031, against roughly $1.0 billion of pretax charges over the same period. Approximately $300 million of these charges are anticipated in fiscal 2027. The company described these figures as estimates that could materially change.

The corporate announcement stated, "This work will result in fewer roles across Nike." Decisions affecting impacted positions will begin in calendar 2027 and beyond. The number and locations of affected roles have not been disclosed.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Broadcom Anthropic Financing Up To $42 Billion

Broadcom Anthropic Financing Up To $42 Billion

Broadcom Anthropic financing of up to $42 billion appears in Anthropic's IPO prospectus, raising concentration and financing risk for IPO investors.

Synopsys Investor Day Raises Growth Targets

Synopsys Investor Day Raises Growth Targets

Synopsys Investor Day raised long-term revenue and margin targets on AI demand and unveiled GPT-Synopsys with OpenAI, likely supporting shares.

McCormick Q3 Results Beat Sales Estimates

McCormick Q3 Results Beat Sales Estimates

McCormick Q3 results beat sales and margins and reaffirmed guidance while raising cost inflation, pushing traders to weigh margins versus higher costs.

Liquidia Patent Ruling Threatens YUTREPIA U.S. Sales

Liquidia Patent Ruling Threatens YUTREPIA U.S. Sales

Liquidia patent ruling found YUTREPIA infringes UTHR's patent, raising the prospect of an FDA-directed withdrawal and prompting investor scrutiny.

Sanofi Regeneron Alliance Expands Pipeline

Sanofi Regeneron Alliance Expands Pipeline

Sanofi Regeneron alliance adds four long-acting antibodies with $1 billion upfront and equal cost and profit sharing, a framework investors will weigh.

Nike Earnings: Q1 Preview Tests Turnaround

Nike Earnings: Q1 Preview Tests Turnaround

Nike earnings arrive after the U.S. close; analysts expect weaker revenue and EPS, and traders will watch Greater China and margins for flow shifts.